Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikiana Simigdala

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Breast Cancer Research : BCR|June 9, 2018
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancerRicardo Ribas, Sunil Pancholi, Aradhana Rani, et al.
Molecular Cancer Therapeutics|June 28, 2015
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In VivoRicardo Ribas, Sunil Pancholi, Stephanie K Guest, et al.
Breast Cancer Research : BCR|December 6, 2019
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancerSunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Oncogene|April 21, 2020
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSunil Pancholi, Ricardo Ribas, Nikiana Simigdala, et al.
Nature Communications|March 14, 2018
Capture Hi-C identifies putative target genes at 33 breast cancer risk lociJoseph S Baxter, Olivia C Leavy, Nicola H Dryden, et al.
Nature Communications|December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistanceLesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
Science Advances|November 14, 2020
The structure-function relationship of oncogenic LMTK3Angeliki Ditsiou, Chiara Cilibrasi, Nikiana Simigdala, et al.
Nature Communications|August 15, 2020
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistanceElodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Breast Cancer Research : BCR|June 9, 2018
Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancerRicardo Ribas, Sunil Pancholi, Aradhana Rani, et al.
Molecular Cancer Therapeutics|June 28, 2015
AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In VivoRicardo Ribas, Sunil Pancholi, Stephanie K Guest, et al.
Breast Cancer Research : BCR|December 6, 2019
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancerSunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas, et al.
Oncogene|April 21, 2020
Tumour kinome re-wiring governs resistance to palbociclib in oestrogen receptor positive breast cancers, highlighting new therapeutic modalitiesSunil Pancholi, Ricardo Ribas, Nikiana Simigdala, et al.
Nature Communications|March 14, 2018
Capture Hi-C identifies putative target genes at 33 breast cancer risk lociJoseph S Baxter, Olivia C Leavy, Nicola H Dryden, et al.
Nature Communications|December 2, 2017
Discovery of naturally occurring ESR1 mutations in breast cancer cell lines modelling endocrine resistanceLesley-Ann Martin, Ricardo Ribas, Nikiana Simigdala, et al.
Science Advances|November 14, 2020
The structure-function relationship of oncogenic LMTK3Angeliki Ditsiou, Chiara Cilibrasi, Nikiana Simigdala, et al.
Nature Communications|August 15, 2020
PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistanceElodie Montaudon, Joanna Nikitorowicz-Buniak, Laura Sourd, et al.
Pageof 2